A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
Recruiting · NCT07142707 · Interventional (participants receive a specific treatment) · Lead sponsor: MBX Biosciences
View the official record on ClinicalTrials.gov →Interventions studied
MBX 4291Placebo
What this trial is about
The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age of \>18 to ≤65 years at the time of signing the informed consent.
- Has a BMI of ≥30 to \<50 kg/m2 at screening and baseline.
- Weight-stable, i.e., no more than ±5% change in body weight for at least 3 months prior to screening and between screening and baseline.
Exclusion criteria
- History of, or currently active, significant illness or medical disorders that in the opinion of the investigator may preclude participants from participating in the study.
- History of currently active pancreatitis, type I and type II diabetes.
- Secondary causes of obesity, including but not limited to hypothalamic, monogenic, syndromic, or endocrine causes.
- A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Where it is running
4 locations listed across 4 US states.
- MBX Biosciences Investigational Site - Doral, Florida, United States
- MBX Biosciences Investigational Site - Lexington, Kentucky, United States
- MBX Biosciences Investigational Site - Kansas City, Missouri, United States
- MBX Biosciences Investigational Site - Knoxville, Tennessee, United States